Lilly's Trulicity Shows Unique Cardiovascular Outcomes Benefit, Albeit A Modest One
At the ADA annual meeting, Lilly reported positive results from REWIND, a cardiovascular outcomes trial studying the GLP-1 agonist Trulicity in a broad population of patients with and without established CV disease.
You may also be interested in...
With business heavily dependent on sales revenue from Medicare Part D and other US government programs, Lilly will be expected to narrow the gap between US prescription and sales growth.
Cardiovascular outcome trials are driving development in blockbuster SGLT-2 inhibitor and GLP-1 agonist classes to look beyond HbA1c levels to focus on cardiovascular and renal protective effects.
Concerns about gastrointestinal tolerability continue to weigh on Lilly’s tirzepatide, despite improvements seen in a Phase II dose-escalation study. Lilly believes the adverse events are manageable.